These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration.
    Author: Hiroi M, Stanczyk FZ, Goebelsmann U, Brenner PF, Lumkin ME, Mishell DR.
    Journal: Steroids; 1975 Sep; 26(3):373-86. PubMed ID: 1198624.
    Abstract:
    A radioimmunoassay (RIA) method for measuring medroxyprogesterone acetate (MPA, Provera) in serum has been developed utilizing benzene:iso-octane extraction, 3H-MPA to assess procedural losses, goat anti-MPA-3-(0-carboxymethyl) oxime-bovine serum albumin serum and dextran-coated charcoal separation. Control serum blanks were undetectable, 200 pg/ml of MPA was measurable with a high reliability, and intra- and interassay coefficients of variation were 6 and 13 percent, respectively. MPA added to control serum was quantitatively recovered. Serum MPA levels measured in 2 women after ingestion of 10 mg MPA rose to 3.4 to 4.4 ng/ml within 1 to 4 hours after oral intake and fell rapidly thereafter to 0.3 to 0.6 ng/ml within 24 hours. Insertion of Silastic intra-vaginal rings (IVRs), containing 100 or 200 mg of MPA, into 4 women for periods of 3 weeks resulted in a rapid rise of serum MPA after insertion, rather stable MPA levels of 0.9 to 1.6 ng/ml while the IVRs were in place, and a rapid decline of serum MPA following IVR removal. Serum estradiol-17beta and progesterone concentrations, measured about 3 times a week in these patients, indicated that ovulation was consistently inhibited. The serum MPA levels observed in this study were approximately 5 times lower than those reported by other investigators using a double-antibody RIA of MPA in unextracted serum. Radioimmunoassay of serum medroxyprogesterone (MPA, Provera) in 7 wo men following oral and intravaginal administration is presented. The assay utilizes benzene: isooctane extraction, tritiated-MPA to assess procedural losses, goat-MPA-(O-carboxymethyl) oxime-bovine serum albumin serum, and dextran coated charcoal separation. Buffer and control serum blanks were indistinguishable from 0. 200 pg/ml of MPA was measurable with high reliability, and intra- and interassy coefficients of variation were 6 and 13%, respectively. Various amounts of MPA added to control serum were measured with accuracy. MPA levels in the 3 women who injested 10 mg of MPA rose to 3.4-4.4 ng/ml within 1-4 hours after oral intake and fell rapidly thereafter to .3-.6 ng/ml within 24 hours. MPA levels in the 4 women with Silastic intravaginal rings (IVRs) containing 100 or 200 mg of MPA rose rapidly after insertion, were rather stable (.9-1.6 ng/ml) while the IVRs were in place, and declined rapidly following IVR removal. Estradiol-17 beta and progesterone levels indicated that ovulation was consistently inhibited. The MPA levels in this study were approximately 5 times lower than those reported by others using a double-antibody radioimmunoassay of MPA in unextracted serum.
    [Abstract] [Full Text] [Related] [New Search]